NCT02192489View on ClinicalTrials.gov

A Phase 2 Study With CC-220 in Skin Sarcoidosis

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 1, 2014

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions
Sarcoidosis
Interventions
DRUG

CC-220 0.3 mg Daily

DRUG

CC-220 0.6mg Daily

DRUG

Placebo

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT02192489 - A Phase 2 Study With CC-220 in Skin Sarcoidosis | Biotech Hunter | Biotech Hunter